Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The potential use of DNA methylation biomarkers to identify risk and progression of type 2 diabetes.

Gillberg, Linn LU and Ling, Charlotte LU orcid (2015) In Frontiers in Endocrinology 6.
Abstract
Type 2 diabetes mellitus (T2D) is a slowly progressive disease that can be postponed or even avoided through lifestyle changes. Recent data demonstrate highly significant correlations between DNA methylation and the most important risk factors of T2D, including age and body mass index, in blood and human tissues relevant to insulin resistance and T2D. Also, T2D patients and individuals with increased risk of the disease display differential DNA methylation profiles and plasticity compared to controls. Accordingly, the novel clues to DNA methylation fingerprints in blood and tissues with deteriorated metabolic capacity indicate that blood-borne epigenetic biomarkers of T2D progression might become a reality. This Review will address the... (More)
Type 2 diabetes mellitus (T2D) is a slowly progressive disease that can be postponed or even avoided through lifestyle changes. Recent data demonstrate highly significant correlations between DNA methylation and the most important risk factors of T2D, including age and body mass index, in blood and human tissues relevant to insulin resistance and T2D. Also, T2D patients and individuals with increased risk of the disease display differential DNA methylation profiles and plasticity compared to controls. Accordingly, the novel clues to DNA methylation fingerprints in blood and tissues with deteriorated metabolic capacity indicate that blood-borne epigenetic biomarkers of T2D progression might become a reality. This Review will address the most recent associations between DNA methylation and diabetes-related traits in human tissues and blood. The overall focus is on the potential of future epigenome-wide studies, carried out across tissues and populations with correlations to pre-diabetes and T2D risk factors, to build up a library of epigenetic markers of risk and early progression of T2D. These markers may, tentatively in combination with other predictors of T2D development, increase the possibility of individual-based lifestyle prevention of T2D and associated metabolic diseases. (Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Frontiers in Endocrinology
volume
6
article number
43
publisher
Frontiers Media S. A.
external identifiers
  • pmid:25870586
  • scopus:84926625108
  • pmid:25870586
  • wos:000378396200001
ISSN
1664-2392
DOI
10.3389/fendo.2015.00043
language
English
LU publication?
yes
id
8911baa9-76ba-46c0-8ba0-c46ef579af6d (old id 5341954)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25870586?dopt=Abstract
date added to LUP
2016-04-01 14:01:17
date last changed
2022-09-20 03:23:50
@article{8911baa9-76ba-46c0-8ba0-c46ef579af6d,
  abstract     = {{Type 2 diabetes mellitus (T2D) is a slowly progressive disease that can be postponed or even avoided through lifestyle changes. Recent data demonstrate highly significant correlations between DNA methylation and the most important risk factors of T2D, including age and body mass index, in blood and human tissues relevant to insulin resistance and T2D. Also, T2D patients and individuals with increased risk of the disease display differential DNA methylation profiles and plasticity compared to controls. Accordingly, the novel clues to DNA methylation fingerprints in blood and tissues with deteriorated metabolic capacity indicate that blood-borne epigenetic biomarkers of T2D progression might become a reality. This Review will address the most recent associations between DNA methylation and diabetes-related traits in human tissues and blood. The overall focus is on the potential of future epigenome-wide studies, carried out across tissues and populations with correlations to pre-diabetes and T2D risk factors, to build up a library of epigenetic markers of risk and early progression of T2D. These markers may, tentatively in combination with other predictors of T2D development, increase the possibility of individual-based lifestyle prevention of T2D and associated metabolic diseases.}},
  author       = {{Gillberg, Linn and Ling, Charlotte}},
  issn         = {{1664-2392}},
  language     = {{eng}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Endocrinology}},
  title        = {{The potential use of DNA methylation biomarkers to identify risk and progression of type 2 diabetes.}},
  url          = {{https://lup.lub.lu.se/search/files/3723493/8314747}},
  doi          = {{10.3389/fendo.2015.00043}},
  volume       = {{6}},
  year         = {{2015}},
}